Insulet | PODD - Operating Profit


Insulet reported $122M in Operating Profit for its fiscal quarter ending in March of 2026.





Operating Profit Change Date
Abbott USD 2.13B 281M Jun/2026
Align Technology USD 191.32M 13.27M Jun/2026
AtriCure USD 9.66M 9.14M Jun/2026
Baxter International USD 276M 210M Jun/2026
Becton, Dickinson and Co. USD 627M 36M Mar/2026
Boston Scientific USD 1.24B 190M Jun/2026
Cardinal Health USD 861M 98M Mar/2026
Cooper Companies USD -31M 243.8M Mar/2026
Dexcom USD 318.3M 63M Jun/2026
Edwards Lifesciences USD 519.5M 4.8M Jun/2026
Eli Lilly USD 9.78B 792M Mar/2026
Globus Medical USD 164M 17.31M Mar/2026
ICU Medical USD 26.09M 770K Dec/2025
Inogen USD -7.79M 728K Sep/2024
Insulet USD 122M 24.3M Mar/2026
Integra LifeSciences USD 41.29M 29.82M Jun/2026
J&J USD 7.48B 860M Jun/2026
Medtronic USD 2.09B 354M Mar/2026
Merit Medical Systems USD 60.4M 16.25M Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Solventum Corp USD 85M 20M Mar/2026
Stryker USD 1.79B 687M Jun/2026
Tandem Diabetes Care USD 8.29M 31.16M Dec/2025
Teleflex USD 37.03M 686K Mar/2026
West Pharmaceutical Services USD 179.1M 2M Jun/2026
Zimmer Biomet Holdings USD 395.1M 92.2M Mar/2026